- Home
- MGRX vs SABS Comparison
MGRX vs SABS Comparison
Compare MGRX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- SABS
- Stock Information
- Founded
- MGRX 2021
- SABS 2014
- Country
- MGRX United States
- SABS United States
- Employees
- MGRX N/A
- SABS N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- SABS Health Care
- Exchange
- MGRX Nasdaq
- SABS Nasdaq
- Market Cap
- MGRX 18.6M
- SABS 15.8M
- IPO Year
- MGRX 2023
- SABS N/A
- Fundamental
- Price
- MGRX $1.73
- SABS $2.19
- Analyst Decision
- MGRX
- SABS Strong Buy
- Analyst Count
- MGRX 0
- SABS 5
- Target Price
- MGRX N/A
- SABS $10.00
- AVG Volume (30 Days)
- MGRX 82.5K
- SABS 145.3K
- Earning Date
- MGRX 08-14-2025
- SABS 08-07-2025
- Dividend Yield
- MGRX N/A
- SABS N/A
- EPS Growth
- MGRX N/A
- SABS N/A
- EPS
- MGRX N/A
- SABS N/A
- Revenue
- MGRX $516,030.00
- SABS $114,698.00
- Revenue This Year
- MGRX N/A
- SABS N/A
- Revenue Next Year
- MGRX N/A
- SABS N/A
- P/E Ratio
- MGRX N/A
- SABS N/A
- Revenue Growth
- MGRX N/A
- SABS N/A
- 52 Week Low
- MGRX $1.32
- SABS $1.00
- 52 Week High
- MGRX $7.66
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- MGRX 53.47
- SABS 50.13
- Support Level
- MGRX $1.42
- SABS $1.97
- Resistance Level
- MGRX $1.76
- SABS $2.25
- Average True Range (ATR)
- MGRX 0.14
- SABS 0.13
- MACD
- MGRX -0.00
- SABS -0.02
- Stochastic Oscillator
- MGRX 58.88
- SABS 56.18
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.